CURRICULUM VITAE

NAME: LOUIS M. FINK, M.D.

ADDRESS: Research Professor

Desert Research Institute

Las Vegas, Nevada

TELEPHONE: BUSINESS: (702) 822-5104

HOME: (702) 845 6826

PERSONAL STATISTICS:

Place of Birth: Brooklyn, New York

Date of Birth: March 28, 1942

Social Security Number: 122-32-9717

MILITARY SERVICE: Major, USAF, Chief of Pathology

Mather Air Force Base Hospital

Mather, CA 9/13/1970-9/8/1972

EDUCATION:

Boston University, Boston, MA B.A. 1961

Albany Medical College, Albany, NY M.D. 1965

POST-GRADUATE PROFESSIONAL EXPERIENCE

Research Professor

Desert Research Institute 2/1/2012-present

Director, Core Laboratories

Nevada Cancer Institute, Las Vegas, NV 4/2005-1/31/2012

Adjunct Professor of Pathology

University of Nevada-Las Vegas, Las Vegas, NV

Adjunct Professor of Pathology

University of Nevada-Reno, Reno, NV 12/2005-Present

Adjunct Professor of Pathology

University of Nevada-Dental School 1/2006-2009

VISN 16 Diagnostic Services Program Manager 8/1998-4/2/2005

Central Arkansas Veterans Healthcare System

Professor, Department of Pathology

University of Arkansas for Medical Sciences 6/1988-4/2/2005

Chief, Pathology and Laboratory Medicine Service, 6/1988-8/1998

Central Arkansas Veterans Healthcare System

Vice Chairman – Department of Pathology 6/1988-2001

University of Arkansas for Medical Sciences

Professor of Surgery 9/1990-2001

University of Arkansas for Medical Sciences

Little Rock, AR

Chief, Clinical Pathology 1982-6/1988

VA Medical Center, Denver, Colorado

Professor of Pathology 1982-1988

University of Colorado Health Sciences Center

Denver, CO

Professor of Pathology 1981-1982

Vanderbilt University, Nashville, TN

Associate Professor of Pathology 1977-1981

University of Colorado Health Sciences Center

Denver, CO

Visiting Associate Professor 1978-1979

Department of Biophysics and Biochemistry

Yale University Medical School

New Haven, CN (in the laboratory of David Ward)

Assistant Professor of Pathology 1972-1977

University of Colorado Health Sciences Center

Denver, CO

Diplomate, American Board of Pathology (AP) 1972

Assistant Professor of Pathology 1970-1972

Columbia University

College of Physicians and Surgeons

New York, NY

Chief Resident 1969-1970

Department of Pathology

Columbia University Hospital, New York, NY

Fellow in Pathology and Medicine 1967-1969

(in the laboratory of I.B. Weinstein)

Institute for Cancer Research

Columbia University College of Physicians and Surgeons

New York, NY

Fellow in Pathology 1966-1967

(in laboratory of R.L. Erikson)

University of Colorado Health Sciences Center

Denver, CO

Internship in Pathology 1965-1966

University of Colorado Health Sciences Center

Denver, CO

GRANTS, PROFESSIONAL COMMITTEES, CONSULTING APPOINTMENTS AND

PROFESSIONAL SOCIETIES

Grants:

United States Public Health Service 1975-1980

Research Career Development Award (USPHS) 1975-1980

Grant to Study Plasma Membrane Alterations 1980-1985

in Transformed Cells, USPHS-NCI

Macy Foundation Grant to teach pathology to 1983-1984

Ph.D. candidates at the Given Institute, Aspen, CO

VA RAGS Grant, Alkaline Phosphatase 1983-1984

Co-Investigator VA Grant Thrombogenic Alterations 1989-1991

in the Perturbed Vascular Endothelium

Co-Investigator VA Merit Review Grant - Regulation of 1990-1994

Thrombomodulin Expression by the Healing Vessel Wall

Co-Principal Investigator VA Research Grant 1990-1992

Hornick Endowment for Research into Stroke and

Related Disorders: Homocysteinuria Heterozygosity and

Antiphospholipid Antibodies in Young Patients with

Cerebro-Vascular Ischemia

Co-Principal Investigator OREF Grant: 1992-1994

Identifying Total Hip Patients at Increased Risk of DVT

Collaborator - NIH 1-R03-DC01985-01A1: Effects of Ethanol 1993-1995

on Photofrin Photodynamic Therapy

Collaborator - UAMS Grant: Methionine Intolerance in 1993-1994

Diabetic Patients with Peripheral Vascular Disease

Co-Principal Investigator RPB & UAMS: Prevention of 1994-1995

Intraocular Fibrin with Recombinant Thrombomodulin and

Activated Protein C & S: Experimental Treatment in a Rabbit Model

Collaborating Investigator, American Heart Association, 1995-1997

Evaluation of Hyperhomocysteinemia in Diabetes Mellitus

Collaborator: The Use of Diaspirin Cross-Linked Hemoglobin 1997-1998

(DCLHb) for the Avoidance or Reduction of Perioperative

Blood Transfusion

Co-Investigator, Arkansas Cancer Research Center: Endothelial 2000-2005

Dysfunction in Intestinal Radiation Toxicity

Co-Investigator, Nova Nordisk/VA: The Effect of VIIa on 2003-2005

Transmembrans Signaling in Prostate Cancer Cells

Co-Investigator, Arkansas Children’s Hospital: Novel Approach 2004-2006

To Improve the Efficacy of Laser Treatment of Port Wine Stain

Co-Investigator, NIH: Thin Film Biosensor Chip for Venous 2004-2008

Thromboembolism Genotyping

Co-Principal Investigator, DOE: Early Detection of Melonoma and 2005-2008

Other Cancers in Residents of Nevada

Principle Investigator, Vascular Birthmarks Foundation 2006-2009

Biology of Juvenile Hemangioma

Principal Investigator, DOD Treatment of Combined Injury Using

Induced Pluripotent (iPS) cell Based Therapy 2007—July2012

Co-Principal Investigator, DOE: The Stem Cell Marker SALL4 and 2008-2011

Circulating Tumor Cells as Biomarkers for Prostate Cancer Prognoses

and Therapeutics

Principal Investigator, DOD: Prevention of Radiation Injury 2009-Dec2011

By the use of Statins

Co-Investigator, SWOG/R01-converesion: Circulating Tumor Cell 2009-2011

Capture & Analysis in Multi-Center Prostate Cancer Trials

Professional Committee and Society Memberships:

Member, Carcinogenesis Program Scientific Review 1976-1980

Committee On DLRDGs VA Central Office, Washington, DC 1983-1994

Association of Pathology Chairmen (APC) Program 1990-1991

Directors Section (PRODS) Organizing Committee

Academy of Clinical Laboratory Physicians and 1990-1991

Scientists (ACLPS), Chairman of Local Program

Committee for National Meeting, Little Rock, AR

American Association for Cancer Research

American Association for Pathologists

American Association for the Advancement of Science

American Society for Cell Biology

American Association Clinical Chemists/National Academy

For Clinical Biochemists

Association of Clinical Scientists

College of American Pathologist (CAP) 1981-present

American Society of Clinical Pathologists 1981-present

International Academy of Pathologists

The International Society on Thrombosis and Hemostasis

American Society of Hematology

Regional Center of Excellence in Biodefense and 2003-2005

Emerging Infectious Disease (UTMB)

International Academy of Clinical and Applied Thrombosis/ 2004-present

Hemostasis

Nevada Development Commission (Life Sciences) 2005-2009

Southwest Oncology Group (SWOG) 2008-present

Consulting Appointments and Honors:

Consultant Pathologist National Jewish Hospital 1986-1988

Consultant to Scientific Advisory Committee of

Integrated Genetics Inc., Framingham, MA 1986-1988

Consultant to Molecular Staging Inc., New Haven, CN 2001-2004

Editorial Board of Human Pathology 1990-2000

Associate Editor for Book Reviews, Human Pathology 1992-1995

Consultant Somatogen Inc., Broomfield, CO

Consultant, Veterans Affairs Committee of the 1991-1994

Association of Pathology Chairman Council

TQI Physician Consultant for Veterans Affairs 1992

(assigned as consultant to San Antonio VA)

ACLPS Executive Committee, President (1999-2000) 1993-2000

Special Contribution Award, Temple, TX 1996

Health Care System

Editorial Board, American Journal of Clinical Pathology 1996-present

College of Medicine Faculty Evaluation Board 1998-2005

Editorial Board, Blood Coagulation and Fibrinolysis 2000-2006

Consultant Syris Scientific, Gray, ME

American Board of Pathology Hematapathology Test Committee 1998-2005

Consultant, Associated Pathologists Chartered (Quest Diagnostics) 2006-present

Evans Award for Outstanding Service – Academy of Clinical 2003

Laboratory Physicians and Scientist

USCAP, Scientific Advisory Board 2009-present

VA COMMITTEES AND CONFERENCES

Blood Utilization Committee (LRVAMC) 1988-1998

Budget Committee (LRVAMC) 1988-1998

Medical Executive Committee (LRVAMC) 1988-1998

Executive Committee of the Medical Staff (LRVAMC) 1988-1998

Partnership Affiliation Council Executive Committee (LRVAMC) 1988-1998

VA Hem-Onc Clinical Problems Conference (LRVAMC) 1988-present

Ambulatory Care Advisory Committee (LRVAMC)

Strategic Planning, (LRVAMC) 1992-1998

VISN 16 Tertiary Care Committee 1999-2005

VISN 16 Health Care Advisory Council 1999-2005

VHA National Lab Standardization Committee 2003-2005

VHA Vista Imaging National Change Control Board 2004-2005

VHA National Pathology Advisory Council (External Member) 2000-2005

VISN 16 Capital Asset Management Board 2000-2005

University of Arkansas for Medical Sciences (UAMS)

Biochemistry Search Committee 1990

Graduate Medical Education Committee (UAMS)

Promotion and Tenure Committee,

Departmental and University of Arkansas School of Medicine 1991-2000

Residency Review/Residency Training Committee

Co-director Pathology Residency Program 1988-2005

Department of Pathology Executive Committee 1988-2005

Search Committee for State Medical Examiner 1991

Search Committee for Chairman of Neurology 1992

Dean's Research Advisory Committee 1992

Dean’s Executive Committee 1988-2004

Practice Development Subcommittee 1996-1998

Committee on Evaluating and Documenting Educational Activities 1996-1998

Copyright and Patent Committee (UAMS); Biotechnology Transfer 1996-1998

Committee

Search Committee for GRECC Director (UAMS) 1997

Search Committee for Genetics Chair (UAMS) 1997

Breast Cancer Research Committee 1999

Cancer Center Scientific Executive Committee 1999-2000

Medical Licenses:

Nevada (Active)

Arkansas (Inactive)

NewYork (Inactive)

Colorado (Inactive)

PUBLICATIONS-Articles (146 total):

1. Dyke PC and Fink LM: Latent choriocarcinoma. Cancer 1967;20:150-154.

2. Fink LM, Goto T, Frankel F and IB Weinstein: Rat liver phenylalanine tRNA: Column

purification and fluorescence studies. Biochem Biophys Res Commun 1968;32:963-970.

3. Fink LM, Nishimura S and IB Weinstein: Modifications of ribonucleic acid by chemical

carcinogens. I. In vitro modifications of transfer ribonucleic acid by N-acetoxy-2-

acetylaminofluorene. Biochem 1970;9:496-502.

4. Weinstein IB, Grunberger D, Fujimura S and LM Fink: Chemical carcinogens and RNA.

Cancer Res 1971;31:651-655.

5. Fink LM, Lanks KW, Goto T and IB Weinstein: Comparative studies on mammalian and

yeast phenylalanine transfer ribonucleic acids. Biochem 1971;10:1873-1878.

6. Levine AF, Fink LM, Weinstein IB and D Grunberger: Effect of N-2-acetylaminofluorene

modification on the conformation of nucleic acids. Cancer Res 1974;34:319-327.

7. Millette RL and LM Fink: The effect of modification of T DNA by the carcinogen N-2-

acetylaminofluorene: Termination of transcription in vitro. Biochem 1975;14:1426-1432.

8. Naughton MA, Merrill DA, McManus LM, Fink LM, Berman E, White MJ and A Martinez-

Hernandez: Localization of the B chain of human chorionic gonadotropin on human tumor cells

and placental cells. Cancer Res 1975;35:1887-1890.

9. Martinez-Hernandez A, Fink LM and GB Pierce: Removal of basement membrane in the

involuting breast. Lab Invest 1976;34:455-462.

10. Jones PA, Laug WE, Gardner A, Nye CA, Fink LM and WF Benedict: In vitro correlates of

transformation in C3H/10T1/2 clone 8 mouse cells. Cancer Res 1976;36:2863-2867.

11. Clarke SM, and LM Fink: Studies on the iodinated surface membrane proteins and

concanavalin A agglutination of transformed Syrian hamster cells. Biochem Biophys Acta

1977;464:433-441.

12. Simpkins H, Fink LM and K Prasad: Radioisotopes in tissues of patients studied at autopsy. N

Eng J Med 1977;296:456.

13. Simpkins H, Fink LM, Prasad K. Radioactivity in organs of patients receiving radioisotopes:

a retraction. N Engl J Med 1977;296(19):1122.

14. Evans RM and LM Fink: Identification of transmembrane bridging proteins in the plasma

membrane of cultured mouse L-cells. Proc Natl Acad Sci USA 1977;74:5341-5344.

15. Clarke SM and LM Fink: The effects of specific antibody-complement-mediated cytotoxicity

on transformed and untransformed Syrian hamster cells. Cancer Res 1977;37:2985-2992.

16. Tucker WS, Kirsch W, Martinez-Hernandez A, and LM Fink: In vitro studies of plasminogen

activator activity in human brain tumors. Cancer Res 1978;38:297-302.

17. Evans RM, Ward DC and LM Fink: Assymmetric distribution of plasma membrane proteins

in mouse L-929 cells. Proc Natl Acad SciUSA 1979;76:6235-6239.

18. Evans RM, Grillo FG and LM Fink: Analysis of transmembrane proteins from eukaryotic

cells. J Supramol Struct 1979;12:403-417.

19. Warren DF, Naughton MA and LM Fink: Agarose-acrylamide gradient gel electrophoresis of

proteins. Anal Biochem 1982;121:331-334.

20. Evans RM and LM Fink: An alteration in the phosphorylation of vimentin-type intermediate

filaments in associated with mitosis in cultured mammalian cells. Cell 1982;29:43-52.

21. Virmani R, Warren D, Rees R, Fink LM and D English: Effects of perfluorochemical on

phagocytic function of leukocytes. Transfusion 1983;23:512-515.

22. Virmani R, Fink LM, Gunter K and D English: Effect of perfluorochemical (PFC) on human

neutrophil function. Transfusion 1984;24:343-347.

23. Nanney L, Fink LM and R Virmani: Morphologic alterations in rabbit lung following

perfluorochemical infusion. Arch Pathol Lab Med 1984;108:631-637.

24. Schultz AL, Fink LM and M Iliff: Immunofixation of cryoglobulins: Pitfalls and solutions.

Clin Chem 1985;31:791.

25. Carson S, Ross S, and L Fink: Effects of detergents on the binding of avidin to biotin.

Biotechniques 1986;4:350-354.

26. Schultz AL and L Fink: What is the most efficient way to evaluate immunoglobulins. Clin

Chem 1986;32:391-392.

27. Pearlman NW, Stiegman GV, Ahnen DJ, Schultz AL and LM Fink: Acid and gastrin levels

following pylor-preserving pancreatic duodenectomy. Arch Surg 1986;121:661-664.

28. Duggan MJ, DiMichele D, Christian J, Fink LM and WE Hathaway: Collagen-binding of Von

Willebrand's Factor Antigen in the classification of Von Willebrand's Disease. Am J Clin Pathol

1987;88:97-102.

29. Beaver TR, Schultz AL, Fink LM, Anderson CA and RE Donahue: Discordance between

Concentration of Prostatic-Specific Antigen and Acid Phosphatase in Serum of Patients with

Adenocarcinoma of the Prostate. Clin Chem 1988;34(4):1524.

30. Taylor EH, Fink LM and AA Pappas: Reproducibility of Creatine Kinase Isoenzyme

Electrophoresis. Clin Chem 1989;34(4):710.

31. Kahn M, Palmer S, Marlar R and LM Fink. A Modified Quantitative Whole Blood Clot Lysis

Method for General Laboratory Analysis of Fibrinolysis. Thromb Res 1990;59: 171-181.

32. Cook JM, Cook CD, Marlar R, Kahn MB, Barone G, Chung SY, Wood R, Harrell J, Fink LM

and JF Eidt. Thrombomodulin Activity in Human Saphenous Veins Before and After Harvest

for Coronary Artery Bypass Grafting. Surgical Forum 1990;XLI:330-2.

33. Howe SE, Grider SL, Lynch DM and LM Fink. Antisperm Antibody to Human Acrosin. Fertil

Steril 1991;55(6):1176-1182.

34. Pappas A, Purnell G, Palmer S, Dalrymple G, Canton M and L Fink. The negative predictive

value of the D-Dimer in suspected acute pulmonary embolus. ASCP 1991;94(4):511-51.

35. Pappas AA, Palmer S, Meece D and LM Fink. Rapid Preparation of Plasma for Coagulation

Testing. Arch Pathol Lab Med 1991;115:816-817.

36. Solis MM, Cook C, Cook J, Glaser C, Light D, Morser J, Yu S, Fink LM and JF Eidt:

Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat

model. J Vasc Surg 1991;4(5):599-604.

37. Cook JM, Cook CD, Kah M, Marlar R, Fink LM and JF Eidt. Intravenous Recombinant

Soluble Human Thrombomodulin Prevents Venous Thrombosis in a Rat Model. J Vasc Surg

1991;14:147-151.

38. Bonelli JE, Fink LM and KJ Voorhees. U.S. Patent 5,126,024: Apparatus and Method for

Concentrating Microorganisms from a Liquid Medium on an Electrode by Electrodeposition,

Colorado School of Mines, 1992.

39. Kendrick VA, Dunn BE, Fink LM, Vannier AM, Humphries ME and AA Pappas. Hepatitis C

and Liver Function in Veterans. Lab Med 1992;23:12.

40. Abian J., Stone A., Morrow M.G., Creer M.H., Fink L.M. and JO Lay. Thermospray High

Performance Liquid Chromatography - Mass Spectrometry of Cyclosporins, Rapid Commun

Mass Spectrom 1992;6:684-689.

41. Collins CL, Schaefer R, Granger J, Fink LM, Xie S-S, Cook C, Hsu P-L and S-M Hsu.

Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adeno-

carcinoma. Am J Pathol 1992;141:4.

42. Hsu S-M, Waldron AJ, Jr., Fink LM, King C, Xie S-S, Mansouri A and B Barlogie. Pathogenic

significance of interleukin-6 in angioimmunoblastic lymphadenopathy (AILD)-type T cell

lymphoma. Human Pathol 1993;24:126-131.

43. Collins CC, Schaefer R, Granger J, Fink LM and S-M Hsu. Thrombomodulin Expression in

Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma. Eur Respir J 1993;3(11):59-

60.

44. Fink L, Edit J, Johnson K, Cook J, Cook C, Morser J, Marlar R, Collins CL, Schaefer R, Xie S-S,

Hsu S-M and P-L Hsu. Thrombomodulin Activity and Localization. Int J Dev Biol 1993;37:221-

226.

45. Montague D, Fink L, Stone A and S Flock. Optical Methods for Tumor Treatment and

Detection: Mechanisms and Techniques in Photodynamic Therapy II. Proc SPIE 1993;1881:52-

59.

46. Read RC, Ziomek S, Tobler G, Harrell JE, Gocio JC, Fink LM, Ranval TJ, Ferris EJ, Harshfield

DL, McFarland DR, Schaefer RF, Purnell GL and RW Barnes. Thromboembolism in Patients

Undergoing Thoracotomy. Ann Thor Surg 1993;56:223-7.

47. Harrison K, Haire WD, Pappas AA, Holdeman DP, Purnell GL, Fink L and GV Dalrymple.

Plasma D-Dimer: A Useful Tool for Evaluating Suspected Pulmonary Embolus. J Nucl Med

1993;34:896-898.

48. Pappas AA, Dalrymple G, Harrison K, Purnell G, Canton M, Palmer S and L Fink. The

Application of a Rapid D-Dimer Test in Suspected Pulmonary Embolus. Arch Pathol Lab Med

1993;117:977-980.

49. Fan K, Dao DD, Schutz M and LM Fink. Loss of Heterozygosity and Expression of p53 Gene

in Human Primary Prostatic Adenocarcinoma. Diagn Mol Pathol 1994;3(4):265-270.

50. Fink LM and P-L Hsu. Bacteriophage Epitope Libraries: Bacteriophage epitope libraries. The

Generation of Specific Binding Proteins and Peptides In Vitro. Virchows Archiv 1994;424:1-6.

51. Pappas AA, Drew MJ, Flick J, Fink L, Fuller GL and AJ Hough. An Introductory Orientation

to Clinical Pathology Core and On-Call Responsibilities. Arch Pathol Lab Med 1994;118:578-583.

52. Solis MM, Vitti M, Cook J, Young D, Glaser C, Light D, Morser J, Wydro R, Yu S, Fink L and

JF Eidt. Recombinant Soluble Human thrombomodulin: A Randomized, Blinded assessment of

Prevention of Venous Thrombosis and Effects on Hemostatic Parameters in a Rat Model.

Thromb Res 1994;73(6):385-394.

53. Abshire TC, Fink LF, Christian J and WE Hathaway. The Prolonged Thrombin Time of

Nephrotic Syndrome. J Pediat Hematol Onc 1995;17(2):156-162.

54. Munshi MN, Stone A, Fink L and V Fonseca. Hyperhomocysteinemia Following a Methionine

Load in Patients with Non-Insulin Dependent Diabetes Mellitus and Macrovascular Disease.

Metabolism 1996;45(1):133-135.

55. Guba SC, Fink LM, and V Fonseca. Hyperhomocysteinemia: An emerging and important risk

factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996;106(6):709-722.

56. Gagne PJ, Vitti MJ, Fink LM, Duncan J, Nix ML, Barnes RW, Hauer-Jensen M, Barone GW, and

JF Eidt. Young Women with Advanced Aortoiliac Occlusive Disease: New Insights. Ann Vasc

Surg 1996;10:546-557.

57. Adcock DM, Fink L, and RA Marlar. A Mechanistic Approach to the Evaluation of

Hereditary Hypercoagulability. Am J Clin Pathol 1997;108(4):434-449.

58. Richter KK, Fink LM, Hughes BM, C-C Sung, and Hauer-Jensen M. Is loss of endothelial

anticoagulant properties responsible for the chronic nature of radiation enteropathy? Radiother

Oncol 1997;44(1):65-71.

59. Fonseca VA, Stone A, Munshi M, Baliga BS, Aljada A, Thusu K, Fink LM, Dandona P, and D

Phil. Oxidative Stress in Diabetic Macrovascular Disease: Does Homocysteine Play a Role?

South Med J 1997;90(9): 903-906.

60. Richter KK, Fink LM, Hughes BM, Sung CC, Hauer-Jensen M. In the loss of endothelial

thrombomodulin involved in the mechanisms of chronicity on late enteropathy? Radiother

Oncol. 1997 Jul;44(1):65-71.

61. Guba SC, Fink LM, and V Fonseca. Hyperhomocysteinemia and Premature Vascular

Occlusive Disease. Am J Med Sci 1998;315(4):279-285.

62. Fonseca V, Mudaliar S, Schmidt B, Fink LM, Kern PA, and Henry RR. Plasma homocysteine

concentration are regulated by acute hyperinsulinemia in diabetic but no type II diabetic

subjects. Metabolism 1998;47(6):686-689.

63. Marlar RA, Joist JH, and LM Fink. Letter re: Pulmonary Embolism. New Engl J Med

1998;339(21):1556-7.

64. Southern FN, Cruz N, Fink LM, Cooney CA, Barone GW, Eidt JF, and Moursi MM.

Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J

Vasc Surg 1998;28(5):909-918.

65. Fonseca V, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM.

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-

dependent diabetes mellitus. J Diabetes Complications 1998;12(4):181-186.

66. Richter KK, Fink LM, Hughes BM, Shmaysani HM, Sung C-C, and M Hauer-Jensen. M.

Differential Effect of Radiation on Endothelial Cell Function in Rectal Cancer and Normal

Rectum. Am J Surg 1998;176(6):642-7.

67. Lue C., Mitani Y, Crew MD, George JF, Fink LM, and SA Schichman. An Automated method

for the Analysis of T Cell Receptor Repertories, Am J Clin Pathol 1999;111(5):683-90.

68. Yao A, Wang J, Fink LM, Hardin JW, and M Hauer-Jensen. Molecular Cloning and Sequence

Analysis of the 5'-Flanking Region of the Sprague-Dawley Rat Thrombomodulin Gene. DNA

Sequence 1999;10(1):55-60.

69. Wang J, Yao A, Wang J-Y, Fink LM, Hardin JW, and M Hauer-Jensen. cDNA Cloning and

Sequencing, Gene Expression, and Immunolocalization of Thrombomodulin in the Sprague-

Dawley Rat. DNA Research 1999;6(1):57-62.

70. Steinemann TL, Whiteside-Michel J, and LM Fink. Activated Protein C Resistance,

Homocystenemia and Normal Tension Glaucoma: Ann Opthalmol Glauc 1999;31(2):122-24.

71. Guba SC, Fonseca V, and LM Fink. Hyperhomocysteinemia and Thrombosis. Semin Thromb

Hemostasis 1999;25(3):291-309.

72. Fonseca V, Guba SC, and LM Fink. Hyperhomocysteinemia and the Endocrine System:

Implications for Atherosclerosis and Thrombosis. Endocr Rev 1999;20(5):738-759.

73. Das S, Reynolds T, Patnaik A, Rais N, Fink LM, and VA Fonseca. Plasma Homocysteine

Concentrations in Type II Diabetic Patients in India: Relationship to Body Weight. J Diabetes

Complications: 1999;13(4):200-203.

74. Williams TM, Burns F, Crisan D, Dumler JS, Fink LM, Frank TS, Greiner T, Kant JA, and V

Matthias-Hagen. Special Report. Goals and Objectives for Molecular Pathology Education in

Residency Programs. J Mol Diag 1999;1:5-15.

75. Hauer-Jensen M, Kong FM, Fink LM, and MS Anscher. Circulating Thrombomodulin

During Radiation Therapy of Lung Cancer. Radiat Oncol Investig 1999;7(4):238-242.

76. Flock ST, Fink LM, and M Waner. U.S. Patent 6,032,070: Method and Apparatus for

Detecting Electro-Magnetic Reflection from Biological Tissue. University of Arkansas, Little

Rock, AR. 2000. (modified and refiled, U.S. Patent 6,272,374, 2001)

77. Baliga BS, Reynolds T, Fink LM, and VA Fonseca. Hyperhomocysteinemia in Type 2

Diabetes: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine. Endocr Practic 2000;6(6);435-441.

78. Cary ER, Fink LM, Stokes SL, Simmons VL, Kaczor DA, Harmon S, Quarles L, Escobar C, and

DJ Maier. Selection and Implementation for Coagulation Instruments/Reagents in a Multiple

Hopsital/Clinic Network. Blood Coagul & Fibrinolysis 2000;11(7):599-608.

79. Kohli M, Schichman SA, Fink LM, and CS Zent. Use of HFE Mutation Analysis for

Hereditary Hemochromatosis: The Need for Physician Education in the Translation of Basic

Science to Clinical Practice. S Med J 2000;93(5):469-471.

80. Fonseca V, Dicker-Brown A, Ranganathan S., Song W, Barnard RJ, Fink LM, and PA Kern.

Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism

2000;49(6):736-741.

81. Amiri M, Schmidley JW, Fink LM, and SM Nazarian. Is testing for inherited coagulation

inhibitor deficiencies in young stroke patients worthwhile? Cli Neurol Neurosur 2001;102(4):219-

222.

82. Dicker-Brown A, Fonseca VA, Fink LM, and PA Kern. The Effect of Glucose and Insulin on

the Activity of Methylene Tetrahydrofolate Reductase and Cystathionine--Synthase: Studies in

Hepatocytes. Atherosclerosis 2001;158:297-301.

83. Poirier LA, Brown AT, Fink LM, Wise CK, Randolph CJ, Delongchamp RR, and VA Fonseca.

Blood S-Adenosylmethionine Concentrations and Lymphocyte Methylenetetrahydrofolate

Reductase Activity in Diabetes Mellitus and Diabetic Nephropathy. Metabolism 2001;50(9):1014-

1018.

84. Wang J, Albertson CM, Zheng H, Fink LM, Herbert J-M, and M Hauer-Jensen. Short-Term

Inhibition of ADP-Induced Platelet Aggregation by Clopidogrel Ameliorates Radiation-Induced

Toxicity in Rat Small Intestine. ThrombHemost 2002;87(1):122-128.

85. Albertson CM, Richter KK, Kudryk BJ, Fink LM, and M Hauer-Jensen. Association between

Decreased Pulmonary Endothelial Cell Thrombomodulin and Local Fibrin Deposition in

Pneumonia. Blood Coagul & Fibrinolysis 2001;12(8):729-733.

86. Zangari M, Anaissie E, Barlogie B, Badros A, Deskian R, Gopal AV, Morris C, Toor A, Siegel E,

Fink L, and G Tricot. Increased Risk of Deep-vein Thrombosis in Patients with Multiple

Myeloma Receiving Thalidomide and Chemotherapy. Blood 2001;98(5):1614-1615.

87. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A,

Whitfield D, Siegel E, Barlogie B, Fink L, and G Tricot. Activated protein C resistance in the

absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated

with an increased risk of thrombotic complications. Blood Coagul & Fibrinolysis 2002;13(3):187-

192.

88. Kohli M, Fink LM, Spencer HJ, and CS Zent. Advanced prostate cancer activates coagulation:

a controlled study of activation markers of coagulation in ambulatory patients with localized

and advanced prostate cancer. Blood Coagul & Fibrinolysis 2002;13(1):1-5.

89. Joseph L, Fink LM, and M Hauer-Jensen. Cytokines in Coagulation and Thrombosis: a

preclinical and clinical review. Blood Coagul & Fibrinolysis 2002;13:105-116.

90. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink LM, and G

Tricot. Thrombogenic activity of Doxorubicin in myeloma patients receiving Thalidomide:

Implications for therapy. Blood 2002:100(4): 1168-1171.

91. Wang J, Zheng H, Ou X, Fink LM, and M Hauer-Jensen. Deficiency of Microvascular

Thrombomodulin and Upregulation of Protease-Activated Receptor 1 in Irradiated Rat

Intestine: Possible Link Between Endothelial Dysfunction and Chronic Radiation Fibrosis AJP

2002:160(6):2063-2072.

92. Joseph J, Washington A, Joseph L, Ranganathan S, Koehler L, Fink L, Hauer-Jensen M, and R

Kennedy. Hyperhomocysteinemia Leads to Adverse Cardiac Remodeling in Hypertensive Rats.

AJP-Heart Circ Physiology 2002;283:H2567-H2574.

93. Bayer-Garner IB, Fink LM, and LW Lamps. Pathologists in a Teaching Institution Assess the

Value of the Autopsy. Arch Pathol Lab Med 2002;126(4):442-447.

94. Kaushal V, Kohli M, Zangari M, Fink LM, and P Mehta. Endothelial Dysfunction in

Antiangiogenesis-Associated Thrombosis (letter to the editor). J Clin Oncol 2002;20:3042-3043.

95. Burke AP, Fonseca V, Kolodgie F, Zieske A, Fink LM, and R Virmani. Increased Serum

Homocysteine and Sudden Death Resulting from Coronary Atherosclerosis with Fibrous

Plaques. Arterioscl Throm Vas 2002;22(11):1936-1941.

96. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink LM, and G Tricot. The Blood Coagulation

Mechanism in Multiple Myeloma. Semin Thromb Hemostasis 2003;29(3):275-281.

97. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddlemon P, Fink LM, Talamo A, Lee C-K,

and G Tricot. Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and

Effect on Survival. Cin Lymphoma 2003;4(1):32-35.

98. Wang J, Shi J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, and

M Hauer-Jensen. Statins Increase Thrombomodulin Expression and Function in Human

Endothelial Cells by a Nitric Oxide-Dependent Mechanism and Counteract Tumor Necrosis

Factor Alpha-Induced Thrombomodulin Downregulation. Blood Coagul & Fibrinolysis

2003:14(6):575-585.

99. Fonseca VA, Fink LM, and PA Kern. Insulin Sensitivity and Plasma Homocysteine

Concentrations in Non-Diabetic Obese and Normal Weight Subjects. Atherosclerosis

2003;167:105-109.

100. Zharov V, Waner M, Ferguson, Eidt J, Howard, and LM Fink. Infrared Imaging of

Subcutaneous Veins. Laser Surg Med 2004;34:56-61.

101. Hauer-Jensen M, Wang J, and LM Fink. Radiation Injury and the Protein C Pathway. Crit

Care Med 2004;32(5): S325-30.

102. Midathada M, Mehta P, Waner M, and LM Fink. Recombinant Factor VIIa in the Treatment

of Bleeding. Am J Clin Pathol 2004;121:124-137.

103. Steinemann TL, Reis IA, Fink LM, Brown HH, Marlar RA. U.S. Patent 6,656,490:

Opthalmologic uses of protein C. The Board of Trustess of the University of Arkansas, 1996.

Issued 2004.

104. Zangari M, Barlogie, B Anaissie E, Jacobson J, Saghafifar F, Eddlemon P, Lee CK, Thertulien R,

Talamo G, Thomas T, Rhee FV, Fassas A, Fink L, Fuido T. Deep Vein Thrombosis in Patients

with Multiple Myeloma Treated with Thalidomide and Chemotherapy: Effects of

Prophylactic and Therapeutic Anticoagulation. Br J Haematol 2004;126(5): 715-21.

105. Wang J, Zheng H, Ou X, Albertson CM, Fink LM, Herbert JM, Hauer-Jensen M. Hirudin

ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy

to minimize side-effects after radiation therapy and as countermeasure against radiation

exposure. J Thromb Haemost. 2004 Nov;2(11):2027-35.

106. Wang J., Zheng H., Qiu X., Kulkarni A., Fink L., Hauer-Jensen M. Modulation of the intestinal

response to ionizing radiation by anticoagulant and non-anticoagulant heparins. Thromb

Haemost 2005; 94: 1054-9.

107. Boerma M, Burton GR, Wang J, Fink LM, McGehee RE, Hauer-Jensen M. Comparative

expression profiling in primary and immortalized endothelial cells: Changes in gene

expression in response to HMG-CoA reductase inhibition. Blood Coagulation Fibrinolysis

2006; 17: 173-80.

108. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C

(aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of

venous thromboembolism. Br J Haematol.2006 Aug;134(4):399-405

109. MehtaJl, Bursac Z, Hauer-Jenson M, Fort C, Fink LM. Comparison of mortality rates in statin

users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006 Oct

1;98(7):923-8.

110. Zangari M, Elice F, Fink L, Tricot G.Thrombosis in Multiple Myeloma. Expert. Rev.

Anticancer Ther. 2007 Mar; 7(3):307-315 (7):595-598.

111. Zangari M, Fink LM et al. Hemostatic dysfunction in paraproteinemias and in

amyloidosis.Seminars in Thrombosis and Hemostasis 2007 June; 33(4):339-349.

112. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, Pacheco R, Bursac Z, Grant A, Mehta JL.

Inflammatory markers, angiographic severity of coronary artery disease and patient

outcome. American Journal of Cardiolgy 2007; 99:879-84. 113. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC, Ma Y. Bmi-1 is a

target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A 2007;

104(25):10494-9. 114. Wang J, Boerma M, Fu Q, Kulkarni A, Fink LM, and Hauer-Jensen M. Simvastatin ameliorates

radiation enteropathy development after localized fractionated irradiation by a protein C-

independent mechanism. Int. J Radiat Oncol Biol Phys 2007; 68(5):1483-90.

115. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of

treatment-associated venous thromboembolism in newly diagnosed multiple myeloma

patients. Blood Coagul Fibrinolysis.2007 Oct;18(7):595-8.

116. Sukhija R, Bursac Z, Kakar P, Fink L, Fort C, Satwani S, Aronow WS, Bansal D, Mehta JL.

Effects of statins on the development of renal dysfunction. Am J Cardiol. 2008 Apr 1; 101(7):

975-9

117. Ross CC, MacLeod SL, Plaxo JR, Froude JW, Fink LM, Wang J, Stites WE, Hauer-Jensen M.

Inactivation of thrombomodulin by ionizing radiation in a cell-free system: possible

implications for radiation responses in vascular endothelium. Radiat Res. 2008 Apr;169(4):408-

16.

118. Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L. Hemostatic effects of

bortezomib treatment in patients with relapsed or refractory of multiple myeloma.

Haematologica. 2008 Jun;93(6):953-4

119. Boerma M, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, McGonigle S, Paradise E,

Sweetnam P, Fink LM, Vozenin-Brotons M, Hauer-Jensen M. Comparative gene expression

profiling in three primary human cell lines after treatment with a novel inhibitor of Rho

kinase or atorvastin. Blood Coagul Fibrinolysis. 2008 Oct;19(7):709- 718.

120. Talamo G, Claxton D, Tricot G, Fink L, Zangari M. Response to bortezomib in refractory type

I cryoglobulinemia. Am. J. Hematol. 2008;

121. Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y. SALL4

is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008 Aug

1;112(3):805-13.

122. Adcock DM, Fink LM, Marlar RA, Cavallo F, Zangari M.The hemostatic system and

malignancy.Clin Lymphoma Myeloma. 2008 Aug;8(4):230-6.

123. Fu Q, Wang J, Boerma M, Berbée M, Qiu X, Fink LM, Hauer-Jensen M. Involvement of heat

shock factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin.

Circ Res. 2008 Aug 15;103(4):369-77.

124. Zangari M, Elice F, Tricot G., Fink L. Thrombomphilia. Drug Target Insights 2008:387-97.

125. Khoury JD, Fink LM, Vogelzang NJ. Call for revision of College of American Pathologists-

mandated requirements for retention of laboratory records and materials. Arch Pathol Lab

Med. 2008 Nov;132(11):1712-3;discussion 1713.

126. Yang J, Chai L, Fowles TC, Alipio A, Xu D, Fink LM, Ward DC, Ma Y. Genome-wide analysis

reveals Sall4 to be a major regulator of pluripotency in murine- mbryonic stem cells. Proc.

Natl Acad Sci USA. 2008 Dec 16;105(50):19756-61.

127. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotype correction of

murine hemophilia A using an iPS cell-based therapy. Proc. Natl Acad Sci USA. 2009 Jan

20;106(3):808-13.

128. Talamo GP, Ibrahm S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in

patients with multiple myeloma can affect the thalidomide-associated venous

thromboembolism. Blood Coagul Fibrinolysis. 2009: 20(5): 337-9.

129. Marcotte R, Arsenault M, Pelletier D, Hebold W, Waner M, and Fink LM. U.S. Patent 7,532,746:

System and method for locating and accessing a blood vessel. Vue Tek Scientific, LLC, Gray,

ME; May 12, 2009.

130. Goodman OB, Fink LM, Symanowski JT, Wong B., Grobaski B, Pomerantz D, Ma Y, Ward D,

Vogelzang NJ. Circulating tumor cells in patients with castration-resistant prostate cancer

baseline values and correlation with prognostics factors. Cancer Epidemiol Biomarkers Prev

2009; 18(6).

131. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients

with cancer receiving antiangiogenesis agents. Journal of Clinical Oncology 2009; 27(29):4865-

73.

132. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma Y.

Generation and Characterization of Functional Cardiomyocytes using Induced Pluripotent

Stem Cells derived from Human Fibroblasts. Cell Biology International 2009; (11):1184-93.

133. O TM, Tan M, Tarango M, Fink L, Mihm M, Ma Y, Waner M. Differential expression of SKI

oncogene protein in hemangiomas. Otolaryngology - Head and Neck Surgery 2009; 141(2): 213-

8.

134. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos

MA, Niesvizky R, & Fink LM. Survival Effect of Venous Thromboembolism in Patients with

Multiple Myeloma Treated With Lenalidomide and High Dose-Dexamethasone. Journal of

Clinical Oncology 2010. 28(1):132-5.

135. Chan F, Goodman O, Fink L, Vogelzang NJ, Pomerantz D, Khoury JD. Dramatically elevated

circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the

prostate. Arch Pathol Lab Med. 2010; 134(1):120-3.

136. Gai H, Nguyen DM, Moon YJ, Aguila JR, Fink LM, Ward DC, Ma Y. Generation of murine

hepatic lineage cells from induced pluripotent stem cells. Differentiation 2010;79(3):171-81.

137. Mehta JL, Bursac Z, Mehta P, Bansal D, Fink LM, MarshJ, Sukhija R & Sachdeva R. Racial

Disparities in Prescriptions for Cardioprotective Drugs and Cardiac Outcomes in Veterans

Affairs Hospitals. American Journal of Cardiology; 2010 Apr 1; 105 (7):1019-23.

138. Alipio Z, Adcock DM, Waner M, O TMJ, Fink LM, Ward DC, Ma Y. Sustained factor VIII

production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-

derived factor VIII producing endothelial cells. Blood Coagulation and Fibrinolysis 2010.

(21):502–504.

139. Alipio Z, Liao W, Roemer E, Waner M, Fink LM, Ward DC, Ma Y. Reversal of hyperglycemia

in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic β-like cells.

Proceedings of the National Academy of Sciences of the USA 2010; 107(30):13426-31. 140. Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacker S, Goodman O, Paz L, Ma Y,

Ward DC, Vogelzang NJ, Fink LM. Increases in quantitiative D-Dimer levels correlate with

progressive disease better than circulating tumor cell counts in patients with refractory

prostate cancer. American Journal of Clinical Pathology, 2010; 134(6):964-9. 141. Leung E LH, Fiscus RR, Tung JW, Tin V PC, Cheung L, Sihoe A DL, Fink LM, Ma Y, Wong

MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like

properties. PLoS One 2010; 5(11):e14062.

142. Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L. Activated Protein C as measured

by residual factor V after Russell’s Viper Venom and activated protein C treatment analyzed

as a continious variable in multiple myeloma and normal controls. Blood Coagulation and

Fibrinolysis. 2011 Jul:22(5)420-3.

143. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in

multiple myeloma and potential protective effect with thalidomide/lenalidomide-based

therapy: review data from phase 3 trials and studies of novel combination regimens. Clinical

Lymphoma Myeloma Leukemia. 2011 Apr;11(2)228-36.

144. Alipio ZA, Jones N, Liao W, Yang J, Kulkarni S, Sree Kumar K, Hauer-Jensen M, Ward DC, Ma

Y, Fink LM. Epithelial to mesenchymal transition (EMT) induced by bleomycin or

TFG(b1)/EGF in murine induced pluripotent stem cell-derived alveolar Type II-like cells.

Differentiation. 2011 Sep. 82(2)89-98.

145. Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ. Circulating

Tumor Cells as a Predictive Biomarker in Patients with Hormone-sensitive Prostate Cancer.

Clinical Genitourin Cancer. 2011 Sep.9(1)31-38.

146. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate

Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in

Patients with Metastic Prostate Cancer. Clinical Genitourin Cancer. 2011 Jun 30.

147. Yang J, Aguila JR, Alipio Z, Lai L, Fink L,Ma Y. Enhanced Self-renewal of Hematopoietic

Stem Cells Mediated by the Stem Cell Factor Sall4. J of Hematology and Oncology 2011;4:38

148. Wang J, Kulkarni A, Chintala M, Fink L, Hauer-Jensen M. Inhibition of Protease-activated

Receptor 1 Mediated Radiation Mucositis in a Preclinical Rat model (Int J Rad Oncol Biol

Physics in press)

149. Xu D, O Mt, Shartava A, Fowles T, Yang J,Fink L, Ward DC, Mihm M, Waner M, Ma

Y.Isolation, Characterization and in vitro Propogation of Infantile Hemangioma Stem Cells

and an invivo Mouse Model. J Hematol Oncol.2011Dec22:4:54.

150. Geiger H, Pawar S, Kerschen J, Nattamai K, Fernandez J, Kustikova O, Schambach A, Fu Q,

Wang J, Fink L, Peterson K, Zhou D, Griffin J, Baum C, Weiler H, Hauer-Jensen M.

Pharmacological targeting of the thrombomodulin-protein C pathway mitigates radiation toxicity.

Nature (in press).

151. Wang J, Kulkarni A, Chintala M, Fink LM, Hauer-Jensen M. Inhibition of protease-activated

receptor 1 ameliorates intestinal radiation mucositis in a preclinical rat model. J. Radiat. Oncol.

Biol. Physics (in press).

152. Biju P, Garg S, Wang W, Choudhry M, Kovacs E, Fink LM, Hauer-Jensen M.Procalcitonin as a

predictive biomarker for total body irradiation induced bacterial load and lethality in mice. Shock

(in press).

.

PUBLICATIONS-Books, Reviews, Chapters in Books, Miscellaneous

1. Weinstein IB and LM Fink. Methods for studying mammalian transfer RNAs. Methods in

Cancer Research, H. Busch, ed., Chapter VII, 1971;311-343.

2. Grunberger D, Weinstein IB, Fink LM, Nelson JH and CR Cantor: Interaction of N-2-

acetylaminofluorene with RNA. In: Prog Mol Subcel Biol F. Hahn, ed., Springer-Verlag, New

York, NY, 1971;2:371-381.

3. Clarke SM, Kohler PF and LM Fink. The use of complement-mediated cytolysis to analyze

specific populations of eukaryotic cells in culture. Methods Cell Biology. D. Prescott, ed.,

Academic Press, New York, 1978;20:484-497.

4. Fink LM, Evans RM, Barret JC and SM Clarke. Cell surface antigens as markers for the

transformed phenotype. In: In Vitro Carcinogenesis. Guide to the Literature, Recent Advances

and Laboratory Procedures. U. Saffiotti and H. Autrup, eds. NCI Carcinogenesis Technical Report

Series No. 44. DHEW Publ. No. (NIH) 780844, 1978.

5. Pierce GB, Shikes RH and LM Fink. Cancer: A Problem of Developmental Biology. Prentice-

Hall, Inc., Englewood, Cliffs, NJ, 1978.

6. Kirsch WM, Tucker WS, Tabuchi K, Fink LM and JJ Van Buskirk. The Metabolism of

Glioblastoma: Pathobiological Correlates. Clin Neurosurg. E. Keener, ed., Williams and Wilkins

Co., Baltimore, 1978; 25:10-25.

7. Fink LM, Clarke SM. Monoclonal antibodies as diagnostic reagents for the identification and

characterization of human tumor antigens. Prog Clin Pathol 1984; 121-133. Review.

8. KiechleFL, Chambers LM, Cox RS, Davis CM, Fink L, Kaul K, and M Duby (Editoral Board).

Patient Preparation and Specimen Handling. Reference Guide for Diagnostic Molecular

Pathology /Flow Cytometry: Fascicle VII. CAP, 1996;1-395.

9. Kiechle FL, Calam R, Davis CM, Fink L, and J Schramom. So you are going to collect a blood

specimen. An introduction to Phlebotomy. CAP. 8th Ed., 1999;10-59.

10. Fink L, Massol N, and A Pappas. Anticoagulation in Handbook of Hematologic Pathology,

Schumacker H, Rock Jr. H, Strass S, Editors. Marcel Dekker, New York, 2000;691-716.

11. Wang J, Shi J, Mehta J, Fink LM, and Hauer-Jensen M. Anticoagulant Effects of Statins.

Statins: Understanding Clinical Use, Mehta, JL. Chapter 12, 2004; 233-256.

12. Marlar RA, Fink LM, and JL Miller. [2007]. Laboratory Approach to Thrombotic Risk. R

McPherson and M Pincus, Henry’s Clinical Diagnosis and Management by Laboratory Methods 21st

ed. (pp.770-777). Philadelphia, Pa: Saunders Elsevier.

13. Fink LM, Marlar RA, and JL Miller. [2007]. Antithrombotic Therapy. R McPherson and M

Pincus, Henry’s Clinical Diagnosis and Management by Laboratory Methods 21st ed. (pp.778-785).

Philadelphia, Pa: Saunders Elsevier.

14. Zangari M, Elice F, Tricot G, and Fink LM. Bleeding Disorders Associated with Cancer

Dysproteinemias. D. Green, and H.C. Kwaan, Coagulation in Cancer, Cancer Treatment and

Research; 148:295-304, DOI 10.1007/978-0-387-79962-9_17, Springer Science +Business Media,

LLC 2009.

15. Marlar RA, Fink LM, and JL Miller. 2011,. Laboratory Approach to Thrombotic Risk. R

McPherson and M Pincus, Henry’s Clinical Diagnosis and Management by Laboratory Methods 22nd

ed. Philadelphia, Pa: Saunders Elsevier.

16. Fink LM, Marlar RA, and JL Miller.2011.Antithrombotic Therapy. R McPherson and M

Pincus, Henry’s Clinical Diagnosis and Management by Laboratory Methods 22 ed. Philadelphia,

Pa:Saunders Elsevier.

17 Zangari M, Berno T, Zhan F, Tricot G, Fink L 2011 Cardiovascular Complications in Patients

with AL Amyloidosis, Amyloidosis - An Insight to Disease of Systems and Novel Therapies, ISBN 978-953-307-795-6,

PUBLICATIONS-Abstracts & Presentations (123 total):

1. Clarke S and LM Fink. Studies on the surface proteins from chemically transformed cells.

Proc Amer Assoc Cancer Res 1976;17:62.

2. Evans RM, Fink LM and SM Clarke. Changes in the distribution of an iodinatable 220,000

MW protein in untransformed and chemically transformed Syrian hamster cells. J Cell Biol

1976;70:248.

3. Tucker WS, Kirsch W, Martinez-Hernandez A and LM Fink. Plasminogen activator activity of

cultured human brain tumor. Annals of Royal College of Physicians and Surgeons of Canada

1976;10:73.

4. Tucker WS, Kirsch W and LM Fink. In vitro fibrinolytic activity of human brain tumors.

Presented at the Annual Meeting of the American Association of Neurological Surgery. Toronto,

April, 1977.

5. Evans RM and LM Fink. Identification of transmembrane bridging proteins in the plasma

membrane of L-cells. Presented at the Cold Spring Harbor Workshop on Cell Transformation, May

18-22, 1977.

6. Imada M, Fink LM and SM Clarke. Heterogeneity of the 220,000 MW proteins of Syrian

hamster cells and analyzed by 2-D electrophoresis. Presented at the Cold Spring Harbor Workshop

on Cell Transformation, May 18-22, 1977.

7. Clarke SM and LM Fink. The effects of specific antibody-complement mediated cytotoxicity

on transformed and untransformed "Syrian" hamster cells. Proc Amer Assoc Cancer Res

1977;18:18.

8. Evans RM and LM Fink. Effects of cytochalasin B and cochicine on phagolysosomal proteins

of mouse cells. Fed Proc 1978;37:1598.

9. Fink LM, Grillo FG and RM Evans. Identification and properties of transmembrane bridging

proteins from mouse cells. J Supramolec Struct Suppl 1979;3:172.

10. Evans RM, Ward DC and LM Fink. Characterization of transmembrane proteins in

phagolysosomes prepared from cultured mouse L-929 cells. Presented at the Cold Spring Harbor

Meeting on the Cytoskeleton: Membranes and Movement, May 16-20, 1979.

11. Evans RM, Ward DC and LM Fink. An alteration in the phosphorylation of vimentin-type

intermediate filaments in associated with mitosis in cultured fibroblasts. Fed Proc 1981;40:1547.

12. Warren DF and LM Fink. An analysis of the protein composition of Con A caps isolated from

mouse L-929 cells. J Cell Biol 1981;91:271.

13. Evans RM and LM Fink. An alteration in the phosphorylation of vimentin-type intermediate

filaments is associated with mitosis in cultured fibroblasts. J Cell Biol 1981;91:237.

14. Chun PKC, McNamara JJ, Fink LM and R Virmani. Perfluorocarbon oxygen transport fluid

oxypherol lowers ST segment and reduces infarct size in baboon. Fed Proc 1983;41(4):793.

15. Virmani R, English D and LM Fink. Effect of perfluorocarbons (PFC) on human neutrophil

function. Fed Proc 1983;42(3):514.

16. Nanney L, Fink LM, Lynch JB and R Virmani. Perfluorocarbon (oxypherol) treatment

induces morphologic changes in rabbit lung. Fed Proc 1983;42(5):1269.

17. Nanney L, Fink L and R Virmani. Morphological demonstration of perfluorocarbon retention

in liver, spleen, lung, and kidney of rabbits. Lab Invest 1983;48:62A.

18. Fink LM and SD Carson. Chemical cross-linking of HeLa cells. Fed Proc 1984;43:1701.

19. Duggan M, DiMichele D, Christian J, Fink LM and WE Hathaway. Uses of Collagen binding of

Von Willebrand's Factor Antigen (VWF:Ag) in the classification of Von Willebrand's Disease

(VWD). Fed Proc 1986;45:967.

20. DiMichele D., Pushchak M, Duggan M, Fink L, Christian J and J Githens. Von Willebrand

Factor (VWF) Collagen-binding (CB) defect in acquired Von Willebrand's Disease (VWD)

associated with spleenic hemangioma. Blood Suppl 1986;68:331.

21. Wilson M, Taylor J, Fink LM and WE Hathaway. An analysis of fibrinogenolysis/fibrinolysis

in patients with liver disease. Clin Chem 1987;33:1004.

22. Abshire T, Fink L, Christian J, O'Connell J and W Hathaway. The dysfibrinogen of childhood

nephrosis. Thromb Hemost 1987;58:147.

23. Wilson M, Aguayo YE, Miller G, Friefeld G and LM Fink. Plasma-D-Dimer Measurements in

the Diagnostic Evaluation of Acute Pulmonary Thromboembolism. Clin Chem 1988;34(6):1303.

24. Broxson EJ, Manco-Johnson M, Jacobson L, Fink L, Marlar R and W Hathaway. Combined

deficiency of protein C and protein S. Blood 1987;70: 367.

25. Bonelli J, Heifets L, Dunn B, Fink L and K Voorhees. Specification of clinically important

Mycobacteria by Curie-point pyralysis-mass spectrometry with spectral pattern recognition.

Amer J Clin Pathol 1988;89: 429.

26. Bonelli J, Fairfax M, Heifets L, Fink L and K Voorhees. Specification of Mycobacteria by

Curie-point Pyrolysis Mass Spectrometry. Proceedings of Academy of Clinical Laboratory

Physicians and Scientists, Annual Meeting, University of Cincinnati, Ohio, June 8-10, 1988.

27. Pappas A, Holder J, Finbeiner A, Cavin L, Komoroski R, Shifman M, Taylor EH, Fink L and G

Dalrymple. In vitro-31-P Magnetic Resonance Spectroscopy and Nuclear DNA Ploidy Patterns

by Flow Cytometry of Prostatic Tumors. Amer J Clin Pathol 1989;89(4):362.

28. Eudy SF, Couch LH, Morrow MG, Fink LM, Taylor EH and AA Pappas. Analysis of Buspirone,

A New Anxiolytic Agent, by High Pressure Liquid Chromatography. Am J Clin Pathol

1989;89(4):368.

29. Palmer S, Curtis B, Campbell P, Mihalko-Ward R, Dihn H and LM Fink. Measurement of D-

Dimers in Patients with Prosthetic Heart Valves. Am J Clin Pathol 1989;92:551.

30. Kahn MS, Palmer S, Fink L and R Marlar. A Modified Quantitative Whole Blood Clot Lysis

Method for use in General Laboratories. Blood 1989;74:392.

31. Pappas AA, Purnell G, Palmer S, Dalrymple G, Canton M and LM Fink. The Negative

Predictive Value of the D-Dimer in Suspected Acute Pulmonary Embolus. Am J Clin Pathol

1990;94(4):111-112.

32. Cook JM, Cook CD, Kahn M, Marlar R, Fink LM and JF Eidt. Thrombomodulin Activity in the

Rabbit Aorta after Endothelial Denudation. Presented at the Zimmerman Memorial Conference:

Progress in Vascular Biology Hemostasis and Thrombosis. LaJolla, California, February 28, 1990.

33. Fink LM, Fink T, Pappas A, Purnell G, Palmer S, Dalrymple G and M Canton. A Prospective

Study on the Predictive Value of the D-Dimer in Suspected Pulmonary Embolus. Poster

presentation at 10th International Congress on Fibrinolysis, Indianapolis, Indiana, August 1990.

34. 34.Eidt J, Cook JM, Cook CD, Kahn M, Marlar R and LM Fink. Thrombomodulin Activity in

the Rabbit Aorta after Endothelial Denudation. Presented at the Biology of Vascular Cells, Vith

International Symposium, Paris, France, August 28-31, 1990.

35. Dunn BE, Morgan PN and LM Fink. Effects of Gentamicin Sulfate (GS) on Polarized LLC-

PK1 Cells. J Cell Biol 1990;111:407.

36. Nehus C, Creer M, Dunn BE, Fink LM and A Pappas. Effect of Bacteriuria on the

Quantitation of Benzoylecogonine by Gas Chromatography Mass Spectroscopy. Am J Clin

Pathol 1991;95:288.

37. Eidt J, Cook J, Hsu S, Hardin R, Hsu J, Marlar R, Cook C and L Fink. Thrombomodulin ™

Activity and Immunohistochemical and mRNA Localization of TM after Balloon Catheter

Intimal Stripping of the Rabbit Aorta. FASEB 1991;5:A1016.

38. Solis MM, Cook JM, Morser J, Fink LM and JF Eidt. The Effect of Recombinant Human

Thrombomodulin in a Rat Model of Venous Thrombosis. Presented at The American Venous

Forum Annual Meeting, Fort Lauderdale, FL, February 20-22, 1991.

39. Stone A, Wheeler M, Lay JO, Walker EM Jr, and LM Fink. Effect of ethanol on tissue

distribution of hematoporphyrin derivative in treated mice. Cancer Res 1991;32:390.

40. Solis MM, Cook C, Light D, Morser J, Fink LM and JF Eidt. A Novel Anti-Thrombotic:

Recombinant Human Thrombomodulin Analogue Prevents Venous Thrombosis in a Rat

Model. Presented at Amsterdam Meeting, 1991.

41. Kendrick V, Dunn BE, Fink LM, Pappas A, Vannier A and M Humphries. The Presence of

Hepatitis - C Virus in Veterans with and without Abnormal Liver Function. Am J Clini Pathol

1991;96:3;419.

42. Santiago ME, Rickman HS and LM Fink. Comparison of prothrombin times derived from

standard methods versus a capillary whole blood measurement system. Arkansas Assoc. Hosp.

Phar. Fall Seminar, Springdale, AR, 1991.

43. Nehus C, Creer MH, Dunn B, Fink L and A Pappas. Effect of Bacteriuria on the Quantitation

of Benzoylecgonine by Gas Chromatography/Mass Spectroscopy, Am J Clin Pathol 1991;95:288.

44. Fan K, Dao DD, Moody MJ, Jacobi S and LM Fink. Loss of p53 Heterozygosity an Lack of ras

Gene Mutation in Human Prostatic Carcinoma. A Correlative Analysis with Morphological

Tumor Gradings, poster presentation, Intl. Academy of Pathology Meeting, Atlanta, GA, 1992.

45. Fan K, Dao D, Moody MJ, Jacobi S, and LM Fink. Expression of ras Gene Family in Human

Prostatic Carcinoma. Lab Invest 1992;66:53A.

46. Nehus C, Hairston K, Badger T, Fink LM and MH Creer. Coaethylene: A Toxicologically

Active Metabolite and Specific Marker of Cocaine and Ethanol Co-Abuse, Am J Clin Pathol

1992;98:364.

47. Morrow M, Blankenship L, Creer MH and LM Fink. Fidelity and Infidelity of Drug Usage

Among Patients in a Drug Rehabilitation Program, Am J Clin Pathol 1992;98:364.

48. Palmer S, Dalrymple G, Harrison K, Purcell G, Fink LM and A Pappas. Use of D-Dimer

Analysis in the Workup of Patients with Suspected Pulmonary Embolism (PE). Clin Lab Sci,

1992;5:3.

49. Ziomek S, Palmer H, Fink L, Tobler HG, Harrell JE Jr, Van Devanter SH and RC Read.

Pulmonary Embolism and Lung Cancer: A Postmortem Study of 482 Patients. Chest

1992;102:2.

50. Dao DD, Fan K, Jacobi SE and LM Fink. Loss of Heterozyosity of p53 and Lack of ras

mutations in human prostatic carcinoma. Proc Am Assoc Cancer Res 1992;33:389.

51. Brown HH, Steinemann TL, Reis IA and LM Fink. Thrombomodulin Expression in Normal

and Neovascularized Ocular Tissues. ARVO Annual Meeting, 1993.

52. Stanley MW, Fink L, Smith D, Skoog L and B Langton. Male Breast Carcinomas do not

Express Immunohistochemically Detectable Levels of C-erB-2 Oncoprotein. Lab Invest

1993;68:20A.

53. Flock S, Montague D, Fink LM, Stone A and E Walker. Effects of Ingested Ethanol on

Photofrin Retention in a Radiation Induced Fibrosarcoma Murine Cancer. American Society for

Laser Medicine and Surgery Abstracts, p52, 1993.

54. James HL, Fink LM and DS Fair. Factor VII Little Rock is Dysfunctional due to an

ARG304to GLN substitution. Thromb Haemost 1993;683:1292.

55. Ranval TJ, Solis MM, Robinson DV, Duncan J, Maraganore J, Yu S, Fink L and JF Eidt.

Recombinant soluble hirudin and its analogues: Prevention of venous thrombosis and effect on

hemostatic parameters in a rat model. Thromb Haemost 1993;2724:1303.

56. Duncan J, Fink L, Dinh H, Iliff M and R Marlar. Monitoring Anticoagulant Therapy in

Patients with Prosthetic Heart Valves. Thromb Haemost 1993;2121:1135.

57. Ziomek S, Read R, Purnell G, Ranval T, Barnes RW, Duncan J, Fink L and R Marlar.

Preoperative Coagulation Studis in Patients Undergoing Thoracotomy. Thromb Haemost

1993;1774:1041.

58. Eidt JF, Marlar RA and L Fink. Identification of an Antibody to Protein S in a Patient with

Multiple Myeloma, Hypercoagulability and Warfarin-Induced Skin Necrosis. Thromb Haemost

1993;224:606.

59. Nazarian SM, Fink LM, Stone A, Duncan JL and LA Kennedy. Baseline and Post-methionine

Load Homocysteine Levels in Patients aged 45 or Younger with Ischemic Stroke. International

Conference on Stroke Prevention and Epidemiology, 1993.

60. Nazarian SM, Fink LM, Duncan JL and LA Kennedy. Anticardiolipin Antibodies, Lupus

Anticoagulant and Hypercoagulability in Patients Aged 45 or Younger with Ischemic Stroke.

International Conference on Stroke Prevention and Epidemiology, 1993.

61. Lay JO, Chiarelli MP, Scott M, and LM Fink. Matrix-Assisted Laser Desorption Time-of-

Flight Mass Spectrometry for the Study of Biotinylated Peptides. Proceedings - Scientific

Conference on Chemical Defense Research, U.S. Army, Edgewood Research Development and

Engineering Center, Aberdeen Proving Ground, MD, November 1993.

62. Robertson RD, Holzman SR, Jensen JC, Johnson DD, Fink LM, Read RC and VS Klimberg.

Chitosan Reduces Intraabdominal Adhesions to Polypropylene Mesh. Am Col Surg, Surgical

Forum XLIV1993;665-66.

63. Flock ST, Blevins S, Lehman P, Franz T, Dinehart S, Waner M, Stern SJ and L Fink. Photofrin

diffusion through mucosal tissue and the effect of carrier molecules. SPIE Proceedings

1994:2133.

64. Munshi M, Stone A, Fink L and V Fonseca. Hyperhomocysteinemia in Diabetic Patients with

Macrovascular Disease. 15th International Diabetes Federation Congress, November 1994.

65. Alleman A, Flock S, Lehman P, Stone A, Fink L, Dinehart S and S Stern. Photofrin and 5-

Aminolevulinic Acid Permeation through Oral Mucosa in vitro. 4th Research Workshop on the

Biology, Prevention and Treatment of Head and Neck Cancer, Arlington, VA, September 1994.

66. Hassell KL, Welsh CH, Fink LM, Kressin DC and RA Marlar. Chronic In Vitro Shear Stress

Model of Endothelial Cell Changes in Pulmonary Hypertension. American Heart Association 67th

Scientific Sessions, Dallas, TX, November 1994.

67. Butch A, Gambrell D, Alton S, Fink L and A Pappas. Comparison and Cost Analysis of Total

T4 Measurements by Several Different Methodologies. AACC 1994.

68. Reis IA, Steinemann TL, Brown HH, Marlar RA and LM Fink. Inihibition of intraocular fibrin

formation following injection of protein C and protein S. ARVO Annual Meeting 1995.

69. Nazarian SM, Fink LM, Stone A and LA Kennedy. Homocysteine Levels in Young Men with

Ischemic Stroke Before and After Folate and Pyridoxine Therapy. J Stroke Cerebrovasc Dis

1995;5(2):98-99.

70. Munshi M, Stone A, Fink L and V Fonseca. Hyperhomocysteinemia in Patients with Diabetes

Mellitus and Macrovascular Disease. Presented at American Association of Clinical

Endocrinologists, April 1995.

71. Nazarian S, Fink L, Stone A and LA Kennedy. Folate Deficiency Leading to

Hyperhomocysteinemia as a Risk Factor for Strokein Men Younger than 45. Eur J Neurol

1995;2(2):12.

72. Fink LM. When blood specimens for coagulation tests are to be drawn through arterial

lines, what is the accepted procedure? Newspath 1996;10(1):4.

73. LM Fink. Guest author for Q & A question. CAP Today 1996;10(1);68.

74. Kendrick V, Cross J, Fink L, and A Pappas. An Analysis of Automated Critical Lab Alerts as

a Notification Tool. Am Assoc Clin Chem;1996.

75. LM Fink. Guest author for Q&A question. CAP Today 1997;11(1):73-74.

76. Fonseca V, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquett T, Graveline J, and L Fink.

Effect of Troglitazone on Fibrinolysis and Coagulation. Diabetes 1997;46,(1), 93A.

77. Veritino AM, LM Fink, and SA Schichman. Quantitative Determination of Bone Marrow

Transplant Engraftment Using Str-Based Human Identity Testing Kits. Assoc Molec Pathol

1997;151(5):1488.

78. Fink LM, Burke AP, Fonseca V, Reynolds T, and R Virmani. Elevated serum homocysteine is

associated with extent of coronary artery atherosclerosis at autopsy, but is not a risk factor for

sudden coronary death. Blood 1997;90(10) Supplement 1 (Part 2 of 2):75b.

79. Fonseca V, Dicker-Brown A, Ranganathan S, Barnard RJ, Fink L, and PA Kern. Effects of

insulin resistance on enzymes of homocysteine metabolism in the rat. A Journal of the American

Diabetes Assoication Abstract Book, 58th Scientific Sessions, June 13-16, 1998;113:0446.

80. AP Burke, L Fink, A Fark, R Virmani. Serum Homocysteine Levels and Sudden Coronary

Death. Lab Invest, 1998;78(1).

81. Mitani Y, Jasin HE, Schichman SA, Fink LM, and C Lue. Oligoclonal Repertoire of Synovial T

Cells in Reactive Arthritis. Arthritis Rheum 1998;41:S346.

82. Fonseca VA, Reynolds T, and LM Fink. Hyperhomocysteinemia and Microalbuminuria in

Diabetes. Diabetes Care, 1998;21(6):1028.

83. Munshi N, Mitani Y, Schichman SA, Buthc A, Rosen N, Fink LM, Vesole D, Singhal S, Desikan

R, Siegel D, Mehta J, Barlogie B, and C Lue. Restricted T-Cell Receptor (TCR) Chain

Repertoire Following T-Cell Depleted Allogeneic Transplantation and Partial Reconstitution

Following Donor Lymphocyte Infusion as Studied by the CDR3 Length Analysis. Blood

1998;92(10):358b.

84. Kohli M, Schichman SA, Fink LM, and CS Zent. Utilization of the HFE Assay for Hereditary

Hemochromatosis in Arkansas. Blood 1998;92(10):17b.

85. Albertson CM, Ricter KK, Martine AR, Kudryk BJ, Fink LM, and M Hauer-Jensen. Association

between Decreased Pulmonary Endothelial Cell Thrombomodulin and Local Fibrin Deposition

in Pneumonia. Thromb Haemost Supplement 1999;460.

86. Wang J, Albertson CM, Zheng H, Fink LM, Herbert J-M, and M Hauer-Jensen. Inhibition of

ADP-Induced Platelet Aggregation Ameliorates Delayed Radiation Toxicity. Thromb Haemost

Supplement 1999;260.

87. Schmidley JW, Amiri M, Fink LM, and SM Nazarian. Utility of Testing Young Patients with

Ischemic Strokes for Inherited Coagulation Inhibitor Deficiences. Stroke – Journal of the

American Heart Association 2000;59:181.

88. Zangari M., Anaissie E., Desikan R., Badros A., Morris C., Munshi N., Gopal AV., Fink L.

Spoon D, Tricot G, and B Barlogie. Thalidomide-induced Hypercoagulability in Multiple

Myeloma (MM). Presented at the International Society of Hematology, December 2000.

89. Albertson CM, Wang J, Zheng H, Fink LM, Herbert J-M, and M Hauer-Jensen. Recombinant

Hirudin, a Direct Thrombin Inhibitor, Ameliorates Radiation Enteropathy. Presented at the

Academy of Clinical Laboratory Physicians and Scientists Meeting. June 2000.

90. Zangari M, Anaissie E, Badros A, Desikan KR, Gopal AV, Morris C, Toor A, eddlemon P, Terry

T, Siegel E, Fink L, Barlogie, and G Tricot. Thrombotic Complications in Myeloma Patients

Receiving Thalidomide in Combination with Chemotherapy. International Society of Thrombosis

and Haemostasis (submitted).

91. Mukunyadzi P, Fan CY, Wilson CS, Givens V, Kohli M, and LM Fink. Loss of syndecan-1 in

prostatic carcinoma: a marker of tumorigenesis. Modern Pathol 2001;14(1):118A.

92. Zangari M, Siegel E, Anaissie E, Saghafifar F, Morris C, Fink L, Barlogie B, and G Tricot. Risk

Factors Factors for Deep Vein Thrombosis (DVT) in a Large Group of Myeloma Patients (Pts)

Treated with Thalidomide (Thal): The Arkansas Experience. Blood 2001;98(11):161a.

93. Kaushal V, Kaushal GP, Anaissie E, Kurylo P, Kohli M, Fink LM, and P Mehta. Thalidomide-

Induced Coagulopathy: Evidence for an Indirect Effect on Endothelium. Blood

2002;100(11):75b.

94. Zangari M, Barlogie B, Anaissie EJ, Saghafifar F, Fassas A, Lee CK, Thertulien R, van Rhee F,

Zeldis J, Fink LM, and G Tricot. Abrogation of Thrombogenic Effect of the Doxorubicin (DOX)-

Thalidomide (THAL) Combination as Part of Total Therapy II (TTII) for Newly Diagnosed

Multiple Myeloma (MM) by Effective Anti-Coagulation with Low Molecular Weight Heparin

(LMWH). Blood 2002;100(11):398a.

95. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Talamo G, Lee

C-K, and G Tricot. The Increased Risk of DVT Observed in Thalidomide Treated Multiple

Myeloma Patients is Associated with Newly Diagnosed Status and Combination Chemotherapy,

but Does Not Adversely Effect Survival. ASCO 2003.

96. Theus J, Hughes S, Flick J, Fink L, and A Pappas. Use of Recombinant Factor VIIa in Diverse

Massive Uncontrollable Surgical Hemorrhage. Annals of Clinical & Laboratory Science

2003;33(3):357.

97. Kaushal K, Mehta P, Fink F. Modulation of Factor VII-Mediated Genes in Prostate Cancer

Cells. AACR Annual Meeting in Orlando, Florida 2004; 45: 4933.

98. Zangari M, Barlogie B, Lee CK, Tricot A, Fassas A, Anaissie E, Hollmig K, Thertulien R,

Talamo G, Van Rhee F, Stover J, Fink L, Tricot G. Protective Effect of VELCADE on

Thalidomide-Associated Deep Vein Thrombosis (DVT). Blood 2004;104(11):310b.

99. Kaushal V, Mehta P, Kohli M, Mukunyadzi P, Dennis R, Fink L. Ets-1 and Tissue Factor

Expression and Regulation in PC3 cells in vitro and in prostate cancer in vivo. AACR 2004.

100. Elice F., Zangari M., Fink L., Barlogie B., and Tricot G. Aquired resistance to activated

protein C (aAPCR) is associated with increased risk of deep vein thrombosis in multiple

myeloma (to be presented Amer. Soc. Hem. Atlanta, Dec 2005)

101. Elice F., Zangari M., Fink L., Barlogie B., and Tricot G. High incidence and transitory nature

of aquired resistence to activated protein C (aAPAR) in patients with multiple myeloma (to be

presented at the Third International Conference on Thrombosis & Hemostasis Issues in Cancer,

Bergamo, Italy Oct. 2005)

102. Kaushal V., Mehta P., Kohli M., Mukunyadizi P., and Fink L. Ets-1 and Tissue Factor:

Regulation and expression in PC-3 cells in vitro and in prostate cancer in vivo. Abstract #4723

Amer. Assoc. Cancer Res. 2005.

103. Kaushal V., Mehta P., Gokden N., and Fink L. Tissue Factor and Factor VIIa regulate

expression of ETS-1 in Prostate Cancer. ISTH Sidney Australia, Aug 2005.

104. Ma Y, Barnett T, Chai L, Yang J, Alipio A, Pei L, Amin HM, Fink L, Di C, Yan H, Ward D.

DEAH-Box Splicing Factor Gene, Prp16 Amplification in Acute Myeloid Leukemia. Session

Type: Publication Only Abstract #4479 Blood, Volume 108, issue 11, November 16, 2006.

105. Zangari M, Cavallo F, Prasad K, Fink L, Coon S, Barlogie B, Tricot G. Erythropoietin Therapy

and Venous Thromboembolic Events in Patients with Multiple Myeloma Receiving

Chemotherapy with or without Thalidomide. Abstract #3572 Blood, Volume 108, issue 11,

November 16, 2006

106. Zangari M, Cavallo F, Fink LM, Barlogie B, Bolejack V, Burns MJ, Anaissie E, Hollmig KA,

Mohiuddin A, Pineda-Roman M, Tricot GJ. Treatment Associated Venous Thromboembolism

(VTE) and Survival in Multiple Myeloma Patients. Session Abstract #3573 Blood, Volume 108,

issue 11, November 16, 2006

107. Yang J, Chai L, Fowles T, Alipio Z, DaSilva K, Tarango M, Volgelzang NJ, Ward DC, Fink LM

and Ma Y. SALL4 is a novel biomarker for human germ cell tumors and stem cells. Abstract #

LB-90 ,AACR, San Fransisco 2007.

108. Fu Q, Wang J, Boerma M, Qiu X, Fink LM, Hauer-Jensen M. Transcriptional regulation of

endothelial cell thrombomodulin by statins. 13th International Congress of Radiation Research,

San Francisco, July 2007

109. Wang J, Boerma M, Fu Q, Fink LM, Hauer-Jensen M. Simvastin ameliorates radiation

enteropathy development after localized, fractionated irradiation by a protein C-

indepentdent mechanism. 13th International Congress of Radiation Research, San Francisco, July

2007

110. Wong B, Fink L, Symanowski J, Pomerantz D, Dincer A, Adcock D and Vogelzang NJ.

Coagulation markers D-dimer and prothrombin fragment 1.2 compared to disease and

treatment status in prostate cancer patients. ASCO Chicago 2007

111. Manno P. J., Vogelzang N, Sharma S, Pomerantz A, Fink L, Halterman P, Caramico S, Faircloth

R and Murdock S. An analysis of sentinel events after the implementation of a comprehensive

information technology system for a new cancer center. ASCO Chicago 2007

112. Ma Y, Yang J, Chai L, Fowles T, Tarango M, Vogelzang NJ, Ward DC, and Fink LM.

SALL4 is a novel biomarker for human germ cell tumors and stem cells. AACR Meeting

Abstracts 2007: LB-90.

113. Goodman G.O., Fink L.M., Symanowski B, Wong D.A., Ward D.C., Vogelzang N.J.

Longitudinal analysis of circulating tumor cell (CTC) counts in assessment of treatment

efficacy. Abstract # 5169, ASCO 2008.

114. Goodman O, Fink L, Symanowski J, Wong B, Pomerantz D, Yupo Ma Y, Grobaski B, Broome

D, Ward D, and Vogelzang N. Utility of circulating tumor cells as a prostate cancer biomarker:

patient clinical characteristics and biomarker cluster analysis. AACR Meeting Abstracts 2008:

997.

115. Gonzales J.C., Fink L.M., Goodman Jr. O.B., Symanowski J.T., Ma Y, Grobaski B.A., Broome

D.T., Vogelzang N.J., Ward D.C.. Comparison of circulating microRNA with velocity of

circulating tumor cells and PSA for determining progression of prostate cancer. AACR

Meeting Abstracts 2009: #1372 A.

116. Khoury J.D., Adcock D.M., Tiefenbacher S., Symanowski J, Goodman Jr. O.B., Ma Y, Ward D.,

Tung J., Grobaski B.A., Vogelzang N.J., Fink L.M.. Changes in circulating tumor cells over time

correlates with D-dimer and serum prostate-specific antigen levels in patients with refractory

prostate cancer. AACR Meeting Abstracts 2009: #LB-260.

117. Zangari, M., Fink, L.M., Zhan, F., Tricot, G.J. Bortezomib Does Not Increase

Thromboembolic Risk in Multiple Myeloma and May Offer a Protective Effect with

Thalidomide/ Lenalidomide-Based Therapy: Review of Data From Phase 3 Trials and Studies

of Novel Combination Regimens. 51st ASH Annual Meeting and Exposition, 2009: Poster Board

I-895.

118. Goldkorn A, Xu T, Lu B, Williams A, Fink LM, Tangen CM, Twardowski G, Tai Y-C, Quinn DI,

Cote RJ, and Southwest Oncology Group (SWOG) Genitourinary Committee. Circulating tumor

cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. ASCO

Meeting 2010; # TPS342.

119. Fink LM. Myeloma and Coagulation. Association of VA Hematology/Oncology (AVAHO)

Annual Meeting. October 9, 2010.

120. Alipio Z, Wu P, Ward DC, Fink LM, Ma Y. Generation of Functional Osteogenic-like Cells

from Murine Induced Pluripotent Stem Cells in 2-Dimensional and 3-Dimensional Culture

Systems. Abcam meeting 2010. Poster presentation October 28, 2010.

121. Alipio Z, Wu P, Ward DC, Fink LM, Ma Y. Derivation of Type II Alveolar Cells from

Induced Pluripotent Stem (iPS) Cells and Their Engraftment in Murine Lung Tissue. Abcam

meeting 2010. Poster presentation October 28, 2010.

122. Alipio Z, Wu P, Ward DC, Fink LM, Ma Y. In vitro Model of Lung Fibrosis Using Induced

Pluripotent Stem Cells-Derived Type II Alveolar Epithelial Cells. Abcam meeting 2010. Poster

presentation October 28, 2010.

123. Goodman OB, Symanowski JT, Fink LM, Vogelzang NJ. Evaluation of oral cyclophosphamide

activity by CTC enumeration in patients with docetaxel-refractory castration-resistant

metastatic prostate cancer: Potential utility in primary refractory disease. ASCO Meeting

2011, #72619.

124. Gonzales J, Fink L. The Reduction on Bmi-1 Expression Increases the Sensitivity of the

Prostate Cancer Cell Line PC3 to X-ray Irradiation; AACR Meeting Orlando 2011

125. Gonzales J, Le T, Fink L, Alipio-Gloria Z. The Use of Induced Pluripotent Stem Cells Derived

Mouse Alveolar Type II-Like Lung Cells (ATII) for Testing Agents to Prevent Lung Injury.

Stem Cells in Drug Discovery and Development. The US Grant, San Diego,November 2,2011. 126. Vogelzang N, Ely B, Fink L et al Circulating Tumor Cell (CTC) are prognostic of overall survival

(OS) in SWOG S0421 Docetaxal+/- atrasentan for metastatic castration resisrant prostate cancer

(mCROC). ASCO2012.